Page 106 - MI-2-1

Microbes & Immunity Advax-adjuvanted typhoid vaccine

Microbiol Res. 2023;14:1457-1469. doi: 10.1016/J.VACCINE.2019.09.074
4. Karkey A, Thwaites GE, Baker S. The evolution of 15. Mai NL, Phan VB, Vo AH, et al. Persistent efficacy of Vi
antimicrobial resistance in Salmonella Typhi. Curr Opin conjugate vaccine against typhoid fever in young children.
Gastroenterol. 2018;34:25-30. N Engl J Med. 2003;349:1390-1391.
doi: 10.1097/MOG.0000000000000406 doi: 10.1056/NEJM200310023491423
5. Levine MM. Use of vaccines for the prevention of typhoid 16. Capeding MR, Teshome S, Saluja T, et al. Safety and
fever. Indian Pediatr. 2003;40:1029-1034. immunogenicity of a Vi-DT typhoid conjugate vaccine:
Phase I trial in Healthy Filipino adults and children. Vaccine.
6. Sarma VN, Malaviya AN, Kumar R, Ghai OP, Bakhtary MM.
Development of immune response during typhoid fever in 2018;36:3794-3801.
man. Clin Exp Immunol. 1977;28:35-39. doi: 10.1016/j.vaccine.2018.05.038
7. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, 17. An SJ, Yoon YK, Kothari S, et al. Immune suppression
Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella induced by Vi capsular polysaccharide is overcome by
typhi live oral vaccine. Vaccine. 1999;17 Suppl 2:S22-S27. Vi-DT conjugate vaccine. Vaccine. 2012;30:1023-1028.
doi: 10.1016/s0264-410x(99)00231-5 doi: 10.1016/j.vaccine.2011.12.046
8. Darton TC, Jones C, Blohmke CJ, et al. Using a human 18. Zuckerman JN, Hatz C, Kantele A. Review of current
challenge model of infection to measure vaccine efficacy: typhoid fever vaccines, cross-protection against paratyphoid
A randomised, controlled trial comparing the typhoid fever, and the European guidelines. Expert Rev Vaccines.
vaccines M01ZH09 with Placebo and Ty21a. PLoS Negl Trop 2017;16:1029-1043.
Dis. 2016;10:e0004926.
doi: 10.1080/14760584.2017.1374861
doi: 10.1371/journal.pntd.0004926
th
19. Griffin TJ 4 , Thanawastien A, Cartee RT, Mekalanos JJ,
9. Sur D, Ochiai RL, Bhattacharya SK, et al. A cluster- Killeen KP. In vitro characterization and preclinical
randomized effectiveness trial of Vi typhoid vaccine in immunogenicity of Typhax, a typhoid fever protein capsular
India. N Engl J Med. 2009;361:335-344. matrix vaccine candidate. Hum Vaccin Immunother.
2019;15:1310-1316.
doi: 10.1056/NEJMoa0807521
doi: 10.1080/21645515.2019.1599674
10. Khan MI, Soofi SB, Ochiai RL, et al. Effectiveness of Vi
capsular polysaccharide typhoid vaccine among children: 20. Juel HB, Thomaides‑Brears HB, Darton TC, et al. Salmonella
A cluster randomized trial in Karachi, Pakistan. Vaccine. Typhi bactericidal antibodies reduce disease severity but do
2012;30:5389-5395. not protect against typhoid fever in a controlled human
infection model. Front Immunol. 2017;8:1916.
doi: 10.1016/j.vaccine.2012.06.015
doi: 10.3389/fimmu.2017.01916
11. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M,
Leibovici L. Vaccines for preventing typhoid fever. Cochrane 21. Petrovsky N, Aguilar JC. Vaccine adjuvants: Current state
Database Syst Rev. 2014;2014:CD001261. and future trends. Immunol Cell Biol. 2004;82:488-496.
doi: 10.1002/14651858.CD001261.pub3 doi: 10.1111/j.0818-9641.2004.01272.x
12. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines 22. Stewart EL, Counoupas C, Johansen MD, et al. Mucosal
for preventing typhoid fever. Cochrane Database Syst Rev. immunization with a delta-inulin adjuvanted recombinant
2018;5:CD001261. spike vaccine elicits lung-resident immune memory and
protects mice against SARS‑CoV‑2. Mucosal Immunol.
doi: 10.1002/14651858.CD001261.pub4
2022;15:1405-1415.
13. Mohan VK, Varanasi V, Singh A, et al. Safety and
immunogenicity of a Vi polysaccharide-tetanus toxoid doi: 10.1038/s41385-022-00578-9
conjugate vaccine (Typbar‑TCV) in healthy infants, 23. Xu S, Yang K, Li R, Zhang L. mRNA vaccine era‑
children, and adults in typhoid endemic areas: A multicenter, mechanisms, drug platform and clinical prospection. Int J
2-cohort, open-label, double-blind, randomized controlled Mol Sci. 2020;21:6582.
phase 3 study. Clin Infect Dis. 2015;61:393-402.
doi: 10.3390/ijms21186582
doi: 10.1093/cid/civ295
24. Honda‑Okubo Y, Cartee RT, Thanawastien A, Seung
14. Capeding MR, Alberto E, Sil A, et al. Immunogenicity, Yang J, Killeen KP, Petrovsky N. A typhoid fever protein
safety and reactogenicity of a Phase II trial of Vi-DT typhoid capsular matrix vaccine candidate formulated with Advax-
conjugate vaccine in healthy Filipino infants and toddlers: CpG adjuvant induces a robust and durable anti‑typhoid
A preliminary report. Vaccine. 2020;38:4476-4483. Vi polysaccharide antibody response in mice, rabbits and

Volume 2 Issue 1 (2025) 98 doi: 10.36922/mi.4497